Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs Sintilimab (Primary) ; Capecitabine; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ORIENT-16
- Sponsors Innovent Biologics
- 03 Apr 2019 Study design was presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 16 Jan 2019 According to an Innovent Biologics media release, first patient has been dosed in this study.
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.